Algernon Pharmaceuticals welcomes Dr. Mark Williams to its Board of Directors

– CANADA, Vancouver –  Algernon Pharmaceuticals Inc. (CSE: AGN | FRA: AGW | OTC: AGNPF), a clinical stage pharmaceutical development company, today announced that Dr. Mark Williams to its Board of Directors, replacing Michael Sadhra who has resigned from the board.

“The Company welcomes Mark back to Algernon as its newest Board member,” said CEO, Christopher Moreau. “His extensive knowledge and background in pre-clinical and clinical drug development and biochemistry will add significant diversity to the skills and experience of our Board.”


Dr. Williams was a co–founder of the Algernon Pharmaceuticals drug repurposing program and was actively engaged as the Company’s Chief Scientific Officer until March 1st, 2021. He has over 15 years of experience in drug and medical device development and has authored multiple patents. He has specific expertise and skillsets in taking companies from the discovery process to Phase 2 trials including cGMP manufacturing and toxicology. He holds a PhD in Microbiology from the University of Alberta, and an MBA from the University of Manitoba

About Algernon Pharmaceuticals Inc.

Algernon is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team